Fractyl Health (GUTS) Q3 2026 earnings review
Fractyl's obesity device passes its trial, but cash runs low
Fractyl Health, a developer of medical devices for obesity, passed its six-month clinical trial test while shutting down its second pipeline program to save cash. Chief executive Harith Rajagopalan said patients treated with its Revita endoscopic procedure kept about 80% of their prior drug-induced weight loss at six months, beating the 67% kept by the comparison group. To make its $31.5 million in cash last into the second quarter of 2027, the company is cutting 45% of its staff and halting internal work on its Rejuva gene therapy.
| Pivotal 6-month weight loss kept | ~80% 67% for the sham comparison group |
|---|---|
| Cash and cash equivalents | $31.5M down from $47.1M last quarter |
| Loss excluding one-offs (Adjusted Ebitda) | -$16.0M -$20.8M a year ago |
| Cash runway outlook | Extended to Q2 2027 target cash burn cut 50% to ~$8M/quarter |
⚖️ Verdict: 🟢 Bullish
The story got better because the positive six-month readout removed the immediate risk of a trial failure and cleared the way for an FDA filing late this year. One caution: the clinical win does not solve the balance sheet. Cash fell by about $16 million in the quarter by our math, leaving the company reliant on loan covenant compliance and needing new funding more than a year before its planned early 2028 launch.
The question now is whether the positive six-month data and cost cuts let Fractyl raise capital on workable terms and clear the 12-month bar. Bulls see the widening treatment gap and new billing code as proof of a commercial category, while skeptics point to omitted full-group regain figures and a cash runway that expires before FDA approval. The 12-month pivotal readout and financing terms in the first quarter of 2027 will tell.
🐂 Bull Case
Revita Passed Its Six-Month Trial Test
Fractyl's future rests on Revita, an outpatient endoscopic procedure designed "to reverse years of diet-induced damage to the gut" so patients keep weight off after stopping obesity drugs like tirzepatide. In October, the 308-patient REMAIN-1 pivotal trial met its first primary goal at six months. "In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance," chief executive Harith Rajagopalan said.
- Weight loss retained at six months: about 80% for Revita patients against 67% for the sham comparison group
- Weight stability: 32% of treated patients regained less than 2% or lost more weight, against 18% for sham
- Safety: zero device-related or procedure-related serious adverse events as of the September 24 cut-off
The result removes the immediate risk of a six-month trial failure and lets the medical device developer file for US Food and Drug Administration (FDA) marketing authorization late this year. The benefit versus the sham procedure nearly doubled between month three and month six, which supports the durability case.
What to watch: the 12-month primary readout in the first quarter of 2027. At least half of treated patients must maintain a 5% total body weight loss to hit the FDA's performance goal.
Billing Code and Medicare Path Advance Launch Plans
Winning regulatory approval only pays off if hospitals have a billing code and insurance coverage to perform the procedure. Fractyl outlined its commercial rollout at its September Investor Day and followed up in October by securing a dedicated billing code from the American Medical Association.
Category III Current Procedural Terminology (CPT) code 1122T takes effect on January 1, 2027, more than a year before the planned US launch in early 2028. The company plans to target the top 100 to 200 accredited US bariatric centers, starting with 30 to 50 centers in year one. Meanwhile, medical societies asked Medicare to include ongoing trials in its proposed coverage program for breakthrough devices.
What to watch: Medicare's decision on its breakthrough device coverage pathway in early January 2027. Including ongoing trials would allow faster government reimbursement as soon as the FDA clears Revita.
🐻 Bear Case
Cash Runs Low Ahead of Review and Debt Rules
Fractyl kept its promise not to issue new stock before the pivotal trial readout, as split-adjusted shares barely moved from the second quarter. However, that discipline left cash and cash equivalents at $31.5 million on September 30, down $15.6 million in three months by our math.
Rajagopalan expects current capital to fund the FDA filing and the 12-month data readout, extending the cash runway into the second quarter of 2027. That projection is "subject to compliance with the minimum liquidity covenant under the Company’s credit agreement", and Fractyl still owes $29.2 million in long-term notes. By our math, a $10 million cash floor leaves only $21.5 million in usable funds before the fourth-quarter severance bills hit. In November, the board added independent director Michael Wartell, "specializing in guiding companies through complex situations".
What to watch: any equity financing or debt restructuring announced before the first quarter of 2027. Even with spending cuts, cash will run out more than a year before the planned early 2028 commercial launch.
All-Comer Regain Numbers Are Only Shown for Subgroups
Fractyl calls the pivotal six-month readout a clear victory across all 308 participants in the main analysis group. For the full group, the release gives the statistical score and states that patients kept about 80% of their prior weight loss versus 67% for sham, without printing the exact percentage of body weight regained across all treated patients.
Instead, the release gives exact weight regain percentages only for a post-hoc breakdown by treatment length. Patients who received 12 to 18 centimeters of ablation regained 4.7% of their weight (107 patients), and those with 20 centimeters or more regained 3.8% (47 patients), compared with 8.2% for sham (74 patients). By our math, those three groups sum to 228 people, leaving 80 trial participants out of the detailed regain figures.
What to watch: the complete 308-patient weight regain percentage in the full medical presentation or FDA filing. A smaller gap across the full group than in the long-ablation subgroups would test payer willingness to cover every procedure.
Risks this quarter didn't answer
Three standing regulatory and commercial concerns received no definitive answers in the third-quarter update.
- FDA regulatory pathway: the agency will decide whether Revita qualifies for the faster De Novo Class II review only "following review of the complete safety dataset" after submission.
- Procedure pricing and unit economics: the release shared patient survey interest and target hospital counts from Investor Day, but disclosed no price per procedure or insurer coverage thresholds.
- Oral obesity drug competition: whether easier-to-take maintenance pills reduce the pool of patients stopping therapy remains untested until commercial launch.
👓 Other Themes
Fractyl Cuts Half Its Staff and Halts Rejuva
"Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity," Rajagopalan said. On October 21, Fractyl announced a 45% workforce reduction, which will cost about $2 million in severance mostly in the fourth quarter. The company also stopped internal work on its Rejuva gene therapy program, "seeking strategic alternatives to maximize the value of the program", to halve quarterly cash burn to $8 million by mid-2027.
💲 Other KPIs
Research and development spending fell 28.7% from a year ago to $12.5 million as pivotal trial enrollment costs wound down and staff expenses dropped. Selling, general and administrative costs moved the other way, rising 18.3% to $6.2 million on higher personnel and stock compensation costs as the team prepared for commercialization.
Working capital — current assets minus current liabilities — dropped by half from $33.9 million in the second quarter to $17.0 million, driven by cash consumption. Total liabilities of $79.1 million now exceed total assets of $65.9 million, widening the stockholders' deficit to $13.2 million from $1.7 million three months ago.
Fractyl completed a 1-for-12 reverse stock split on October 2 to cure its stock-exchange minimum bid deficiency. Weighted-average shares rose 145.9% from a year ago because of the August and September 2025 financings, but rose just 0.2% from the second quarter by our math. Excluding $4.2 million in non-cash warrant and debt accounting gains, the net loss was $18.4 million by our math.
🔮 Guidance
Raised. The restructuring extends the expected cash runway from early 2027 into the second quarter of 2027. That covers the planned FDA filing in late 2026 and the 12-month pivotal readout in the first quarter of 2027, provided the company stays above the minimum cash floor in its loan agreement.
New. Management expects to cut quarterly operating cash spending by about 50%, to roughly $8 million, by the end of the second quarter of 2027. The savings come from laying off 45% of the staff, halting internal Rejuva gene therapy work, and finishing the main phase of the REMAIN-1 clinical trial.
Unchanged on filing, with new downstream dates. The medical device maker still plans to submit its FDA De Novo application in late 2026 and report 12-month trial data in the first quarter of 2027. It newly specified targets for potential FDA marketing authorization in late 2027 and a US commercial launch in early 2028.
❓ Key Questions
What was the exact weight regain across all 308 patients?
The release gave exact weight regain percentages for 154 treated patients in two ablation-length subgroups and 74 sham patients. Disclosing the mean percentage weight regain for the full 308-patient group will show how the remaining 80 participants performed.
How will Fractyl fund operations between mid-2027 and early 2028?
Cash runs into the second quarter of 2027, while FDA authorization is slated for late 2027 and commercial launch for early 2028. Even at the reduced $8 million quarterly burn rate, the company needs new capital or a debt amendment soon.
What role will new director Michael Wartell play in financing?
Fractyl expanded its board in November to add Michael Wartell, citing his experience guiding companies through complex situations. Clarifying whether his mandate covers debt renegotiation, an equity raise, or selling the Rejuva gene therapy assets matters for existing holders.
What procedure price did Fractyl model for its target hospitals?
Management outlined a first-year rollout to between 30 and 50 bariatric centers and secured a billing code for January 2027, but has not published an expected price per procedure in its releases.